(Q51478128)

English

Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes.

scientific article published in March 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17300593

Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. (English)

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17300593

type 2 diabetes

0 references

0 references

author name string

Rosenstock J

1

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17300593

Kim SW

2

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17300593

Baron MA

3

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17300593

Camisasca RP

4

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17300593

Cressier F

5

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17300593

Couturier A

6

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17300593

Dejager S

7

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17300593

publication date

1 March 2007

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17300593

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17300593

9

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17300593

175-185

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17300593

2

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17300593

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00698.X

21 January 2018

Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00698.X

21 January 2018

The burden of treatment failure in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00698.X

21 January 2018

Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00698.X

21 January 2018

Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00698.X

21 January 2018

Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00698.X

21 January 2018

Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00698.X

21 January 2018

Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00698.X

21 January 2018

Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00698.X

21 January 2018

Long-term effects of pioglitazone and metformin on insulin sensitivity in patients with Type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00698.X

21 January 2018

Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00698.X

21 January 2018

Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00698.X

21 January 2018

Combination therapy with nateglinide and a thiazolidinedione improves glycemic control in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00698.X

21 January 2018

Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00698.X

21 January 2018

Thiazolidinediones

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00698.X

21 January 2018

Pioglitazone reduces islet triglyceride content and restores impaired glucose-stimulated insulin secretion in heterozygous peroxisome proliferator-activated receptor-gamma-deficient mice on a high-fat diet

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00698.X

21 January 2018

Targeting insulin resistance and beta-cell dysfunction: the role of thiazolidinediones

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00698.X

21 January 2018

Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00698.X

21 January 2018

Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00698.X

21 January 2018

Identifiers

10.1111/J.1463-1326.2006.00698.X

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17300593

1 reference

Europe PubMed Central

5 April 2018

http://europepmc.org/abstract/MED/17300593

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51478128&oldid=934335997"